In this episode, Professor Escudier from Gustave Roussy, a major cancer center in Paris France, discusses the advances in kidney cancer treatment over the past 30 years. Professor Escudier discusses the significance of the Keynote 564, the first positive trial in adjuvant renal cell cancer. He explains how these findings impact first-line treatment decisions for metastatic kidney cancer. He discusses the differences between cure, complete response and the role of the MDT, clinical and pathological biomarkers in treatment selection. Professor Escudier especially covers the questions that he patient should their doctors concerning their renal cancer and defines the differences between Clear Cell and Non-Clear Cell renal cancer treatment outcomes and expectations.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.
This is Gavin Newsom
I’m Gavin Newsom. And, it’s time to have a conversation. It’s time to have honest discussions with people that agree AND disagree with us. It's time to answer the hard questions and be open to criticism, and debate without demeaning or dehumanizing one other. I will be doing just that on my new podcast – inviting people on who I deeply disagree with to talk about the most pressing issues of the day and inviting listeners from around the country to join the conversation. THIS is Gavin Newsom.